Ability Pharmaceuticals
PrivateLast Round
Early Funding
Mar 11, 2024
Est. Valuation
$31.43M
Total Funding Raised
$12.95M
Company Overview
Ability Pharmaceuticals is a biopharmaceutical company that develops oral targeted anticancer compounds for the treatment of various cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ability Pharmaceuticals Comparables
Compare Ability Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Inflection Biosciences | 84% | |
| Kazia Therapeutics | 79% | |
| Celcuity Inc. | 77% |
Ability Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Mar 11, 2024 | ||||
| Grant | Nov 21, 2022 | ||||
| Grant | Oct 7, 2022 | ||||
| VC Round | Oct 22, 2020 | ||||
| VC Round | Mar 16, 2020 | ||||
VC Round | Sep 12, 2019 |
Key People
Founding team and executive leadership
Carles Domenech
Executive Chairman And Chief Executive Officer, Executive Chairman And Chief Scientific Officer At Ability Pharmaceuticals, Chief Executive Officer VP Business Development And Licensing
Ability Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council Fund | Early Funding |
| CDTI Innvierte | Early Funding |
| ACCIÓ - Agency for Business Competitiveness | Seed |
| Inveready | VC Round, Early Funding |
| CTI Life Sciences Fund | Early Funding |
| Founders Fund | Seed |
| Center for Technological Development and Innovation | Early Funding, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 13, 2026
Monthly visitors increased 49% MoM, reaching 1K.
- Mar 11, 2024
$7.65M raised from CTI Life Sciences Fund and Inveready.
Ability Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Ability Pharmaceuticals's valuation, stock price, and market status.
Is Ability Pharmaceuticals a public or private company?
Ability Pharmaceuticals is a private company.
What is the current stock price of Ability Pharmaceuticals?
Ability Pharmaceuticals is a private company with no public stock price. No recent secondary market data is available.
How much is Ability Pharmaceuticals worth (valuation)?
Ability Pharmaceuticals's valuation is estimated at $31.4M based on funding round data.
Can I buy Ability Pharmaceuticals stock?
Ability Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Ability Pharmaceuticals's last funding round?
Ability Pharmaceuticals's most recent funding round was Early Funding on March 11, 2024.
Who are the main investors in Ability Pharmaceuticals?
Key investors in Ability Pharmaceuticals include European Innovation Council, Inveready, CTI Life Sciences Fund, EIC Fund.
Will Ability Pharmaceuticals IPO soon?
No public IPO plans have been announced for Ability Pharmaceuticals.
How can I track Ability Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Ability Pharmaceuticals's secondary market activity and sign up for updates.